Literature DB >> 18393813

Advanced nebulizer designs employing vibrating mesh/aperture plate technologies for aerosol generation.

J C Waldrep1, R Dhand.   

Abstract

Recent technological advances and improved nebulizer designs have overcome many limitations of jet nebulizers. Newer devices employ a vibrating mesh or aperture plate (VM/AP) for the generation of therapeutic aerosols with consistent, increased efficiency, predominant aerosol fine particle fractions, low residuals, and the ability to nebulize even microliter volumes. These enhancements are achieved through several different design features and include improvements that promote patient compliance, such as compact design, portability, shorter treatment durations, and quiet operation. Current VM/AP devices in clinical use are the Omron MicroAir, the Nektar Aeroneb, and the Pari eFlow. However, some devices are only approved for use with specific medications. Development of "smart nebulizers" such as the Respironics I-neb couple VM technologies with coordinated delivery and optimized inhalation patterns to enhance inhaled drug delivery of specialized, expensive formulations. Ongoing development of advanced aerosol technologies should improve clinical outcomes and continue to expand therapeutic options as newer inhaled drugs become available.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18393813     DOI: 10.2174/156720108783954815

Source DB:  PubMed          Journal:  Curr Drug Deliv        ISSN: 1567-2018            Impact factor:   2.565


  18 in total

1.  A novel micropump droplet generator for aerosol drug delivery: Design simulations.

Authors:  Guoguang Su; P Worth Longest; Ramana M Pidaparti
Journal:  Biomicrofluidics       Date:  2010-11-19       Impact factor: 2.800

Review 2.  Fugitive aerosols in the intensive care unit: a narrative review.

Authors:  Ciarraí O'Toole; Mary Joyce; James A McGrath; Andrew O'Sullivan; Miriam A Byrne; Ronan MacLoughlin
Journal:  Ann Transl Med       Date:  2021-04

Review 3.  Aerosol therapy for obstructive lung diseases: device selection and practice management issues.

Authors:  Michael W Sims
Journal:  Chest       Date:  2011-09       Impact factor: 9.410

4.  Effect of formulation on the stability and aerosol performance of a nebulized antibody.

Authors:  Renaud Respaud; Denis Marchand; Christelle Parent; Thibaut Pelat; Philippe Thullier; Jean-François Tournamille; Marie-Claude Viaud-Massuard; Patrice Diot; Mustapha Si-Tahar; Laurent Vecellio; Nathalie Heuzé-Vourc'h
Journal:  MAbs       Date:  2014-10-30       Impact factor: 5.857

5.  Following the concentration of polymeric nanoparticles during nebulization.

Authors:  Moritz Beck-Broichsitter; Marie-Christine Knuedeler; Thomas Schmehl; Werner Seeger
Journal:  Pharm Res       Date:  2012-07-18       Impact factor: 4.200

6.  Aerosol Delivery of siRNA to the Lungs. Part 1: Rationale for Gene Delivery Systems.

Authors:  Susanne R Youngren-Ortiz; Nishant S Gandhi; Laura España-Serrano; Mahavir B Chougule
Journal:  Kona       Date:  2015-09-30       Impact factor: 2.897

7.  Aerosolized drug-loaded nanoparticles targeting migration inhibitory factors inhibit Pseudomonas aeruginosa-induced inflammation and biofilm formation.

Authors:  Mohammad Doroudian; Andrew O'Neill; Ciaran O'Reilly; Aisling Tynan; Leona Mawhinney; Aoife McElroy; Shanice S Webster; Ronan MacLoughlin; Yuri Volkov; Michelle E Armstrong; George A O'Toole; Adriele Prina-Mello; Seamas C Donnelly
Journal:  Nanomedicine (Lond)       Date:  2020-11-26       Impact factor: 5.307

8.  Formulation for a novel inhaled peptide therapeutic for idiopathic pulmonary fibrosis.

Authors:  Soraya Hengsawas Surasarang; Galina Florova; Andrey A Komissarov; Sreerama Shetty; Steven Idell; Robert O Williams
Journal:  Drug Dev Ind Pharm       Date:  2017-11-10       Impact factor: 3.225

9.  Pulmonary monoclonal antibody delivery via a portable microfluidic nebulization platform.

Authors:  Christina Cortez-Jugo; Aisha Qi; Anushi Rajapaksa; James R Friend; Leslie Y Yeo
Journal:  Biomicrofluidics       Date:  2015-04-08       Impact factor: 2.800

10.  Evaluation of patient-reported outcomes and quality of life with the I-neb AAD system in patients with chronic obstructive pulmonary disease.

Authors:  Nicola Goodman; Mike Morgan; Kurt Nikander; Sarah Hinch; Steven Coughlin
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2010-04       Impact factor: 2.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.